Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023, New Report Launched

Diagnosed Prevalent Cases in Seven Major Markets

As shown in the Figure below, the diagnosed prevalent cases of Amyotrophic Lateral Sclerosis (ALS) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) will increase from 32,698 cases in 2013 to 37,122 cases in 2023, at a growth rate of 13.5% over the forecast period. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan, where the two markets combined will constitute more than 50% of the diagnosed prevalent cases in the 7MM. Publisher epidemiologists attribute the growth in the diagnosed prevalent cases of ALS in the 7MM to the changing population demographics in the respective markets.

Publisher's report "Epicast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023", provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the 7MM. In addition, the report includes a 10-year epidemiological forecast (2013-2023) for the diagnosed prevalent cases of ALS segmented by sex and age (in 10-year age groups, beginning at age 40 years and ending at age =80 years). To forecast the diagnosed prevalent cases of ALS in the 7MM, Publisher epidemiologists used only country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global ALS market.
• Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.

Read more about this report at: http://mrr.cm/ZGs

For all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare